Anti-fibrotic therapy: lost in translation? (Q37980899)

26 August 2017

Anti-fibrotic therapy: lost in translation? (English)

1 reference

26 August 2017

1

Detlef Schuppan

1 reference

26 August 2017

Massimo Pinzani

2

1 reference

26 August 2017

1 January 2012

1 reference

26 August 2017

Journal of Hepatology

1 reference

26 August 2017

56 Suppl 1

1 reference

26 August 2017

S66-74

1 reference

Update on the pathophysiology of liver fibrosis

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Mechanisms of hepatic fibrogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

1 reference

7 January 2021

Reversal of hepatic fibrosis -- fact or fantasy?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Reversibility of hepatic fibrosis in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Portal hypertension and iron depletion in patients with genetic hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

1 reference

7 January 2021

Gene expression profiles during hepatic stellate cell activation in culture and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Targeted therapy of liver fibrosis/cirrhosis and its complications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Liver fibrosis: from the bench to clinical targets

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Angiogenesis in liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Hydroxypyridinium collagen cross-links in human liver fibrosis: study of alveolar echinococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Suppression of type I collagen production by microRNA-29b in cultured human stellate cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

MicroRNAs and the regulation of fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Suppression of hepatic stellate cell activation by microRNA-29b.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

MR imaging of liver fibrosis: current state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Role of alphavbeta6 integrin in acute biliary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960008-7

7 January 2021

10.1016/S0168-8278(12)60008-7

Identifiers

DOI

1 reference

release_lnwkfklpqndyrohw7ko23tteoe

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lnwkfklpqndyrohw7ko23tteoe

24 November 2022

mapped directly with Wikidata item

PubMed ID

22300467

1 reference

PubMed ID

22300467